Pinpointing Patients Who Require Aggressive Treatment

Drs. Richard Choo and Laurence Klotz (1997 Research Grant)

One of the most influential prostate cancer studies was funded by the Foundation almost a decade ago. It was a long-term study on watchful waiting by Drs. Richard Choo and Laurence Klotz.

Although most prostate cancer is slow growing, some cases are aggressive and warrant immediate radical treatment. In the absence of a crystal ball, doctors and patients are faced with a treatment dilemma: fight the disease with radical treatments that can lower quality of life or exercise watchful waiting and risk missing the opportunity for a cure?

In a phase II clinical study, the researchers tested a novel approach. They used a man’s PSA doubling time to choose a treatment path. The study found that men with “favourable risk” prostate cancer (gleason score of 6 or less, PSA less than 10 and cancer stage T1c to T2a) can be safely monitored with watchful waiting and almost all of them will die of unrelated causes. This finding is significant because half of new diagnoses fall into this category. The study suggests that at least 40 per cent of men can be spared the debilitating effects of radical treatment without sacrificing life expectancy.

Although it is still ongoing, the study has already had a huge impact on patient care. A larger phase III trial is now taking place in Canada, the USA, UK and Europe.



Plaid for Dad


Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Honouring dad this Father’s Day the Canadian way: In plaid

TORONTO, ON – (May 8, 2018) – Plaid replaces business-casual on Friday, June 15 as hundreds of thousands of Canadians don the iconic Canadian attire all to honour dad and end prostate cancer.
More

The Finger – A tried and true method to save lives

TORONTO, CANADA (May 8, 2018) – Every day, more and more methods to detect prostate cancer are being explored, but the tried and true methods of a digital rectal examination (DRE) – where a healthcare professional inserts a gloved finger into the rectum to check for abnormalities, paired with a blood test known as the prostate-specific antigen (PSA) test – which you can get through your family doctor, are still the long-standing proven ways to save a life.
More

Landmark study links tumour evolution to prostate cancer severity

Toronto (April 19, 2018) – Findings from Canadian Prostate Cancer Genome Network (CPC-GENE) researchers and their collaborators, published today in Cell, show that the aggressiveness of an individual prostate cancer can be accurately assessed by looking at how that tumour has evolved.
More


Click here for news archive